TY - JOUR
T1 - Human Immunocompetent Model of Neuroendocrine Liver Metastases Recapitulates Patient-Specific Tumour Microenvironment
AU - Doornebal, Ewald Jan
AU - Harris, Nicola
AU - Riva, Antonio
AU - Jagatia, Ravi
AU - Pizanias, Michail
AU - Prachalias, Andreas
AU - Menon, Krishna
AU - Preziosi, Melissa
AU - Zamalloa, Ane
AU - Miquel, Rosa
AU - Zen, Yoh
AU - Orford, Michael Robert
AU - Eaton, Simon
AU - Heaton, Nigel
AU - Ramage, John
AU - Palma, Elena
AU - Srirajaskanthan, Rajaventhan
AU - Chokshi, Shilpa
N1 - Copyright © 2022 Doornebal, Harris, Riva, Jagatia, Pizanias, Prachalias, Menon, Preziosi, Zamalloa, Miquel, Zen, Orford, Eaton, Heaton, Ramage, Palma, Srirajaskanthan and Chokshi.
PY - 2022
Y1 - 2022
N2 - Neuroendocrine liver metastases (LM-NEN) develop in a considerable proportion of patients with gastroenteropancreatic neuroendocrine neoplasms. There is a paucity of experimental models that accurately recapitulate this complex metastatic human liver microenvironment precluding scientific and clinical advancements. Here, we describe the development of a novel personalised immunocompetent precision cut tumour slice (PCTS) model for LM-NEN using resected human liver tissue. The histological assessment throughout the culture demonstrated that slices maintain viability for at least 7 days and retain the cellular heterogeneity of the original tumour. Essential clinical features, such as patient-specific histoarchitecture, tumour grade, neuroendocrine differentiation and metabolic capacity, are preserved in the slices. The PCTS also replicate the tumor-specific immunological profile as shown by the innate and adaptive immunity markers analysis. Furthermore, the study of soluble immune checkpoint receptors in the culture supernatants proves that these immunomodulators are actively produced by LM-NEN and suggests that this process is epithelium-dependent. This model can be employed to investigate these pathways and provides a powerful platform for mechanistic, immunological and pre-clinical studies.
AB - Neuroendocrine liver metastases (LM-NEN) develop in a considerable proportion of patients with gastroenteropancreatic neuroendocrine neoplasms. There is a paucity of experimental models that accurately recapitulate this complex metastatic human liver microenvironment precluding scientific and clinical advancements. Here, we describe the development of a novel personalised immunocompetent precision cut tumour slice (PCTS) model for LM-NEN using resected human liver tissue. The histological assessment throughout the culture demonstrated that slices maintain viability for at least 7 days and retain the cellular heterogeneity of the original tumour. Essential clinical features, such as patient-specific histoarchitecture, tumour grade, neuroendocrine differentiation and metabolic capacity, are preserved in the slices. The PCTS also replicate the tumor-specific immunological profile as shown by the innate and adaptive immunity markers analysis. Furthermore, the study of soluble immune checkpoint receptors in the culture supernatants proves that these immunomodulators are actively produced by LM-NEN and suggests that this process is epithelium-dependent. This model can be employed to investigate these pathways and provides a powerful platform for mechanistic, immunological and pre-clinical studies.
KW - Humans
KW - Liver Neoplasms/secondary
KW - Neuroendocrine Tumors/pathology
KW - Tumor Microenvironment
U2 - 10.3389/fendo.2022.909180
DO - 10.3389/fendo.2022.909180
M3 - Article
C2 - 35909511
SN - 1664-2392
VL - 13
SP - 909180
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
ER -